ArticleThe Journal of antibiotics2025
Kaempferol inhibits lipid accumulation in alcoholic fatty liver disease through PRMT-1-mediated arginine methylation of SCD1.
Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcoholic fatty liver disease (AFLD) is a type of liver damage caused by excessive alcohol consumption. Kaempferol (Kae) has been shown to have good anti-cancer effects. This study aimed to investigate the effect and the mechanism of Kae on AFLD at the cellular level. THLE-2 cells were treated with ethanol to establish an AFLD cell model. The effect of Kae on lipid accumulation was assessed through the level of intracellular triglyceride (TG), intracellular total cholesterol (TC), cellular lipid accumulation and lipids metabolism-related genes, which were detected by a TG kit, a TC kit, Oil red O staining and quantitative real-time PCR, respectively. Western blot was used to measure the level of asymmetric dimethyl arginine (ADMA), and PRMTs expression was assessed by qPCR. The underlying mechanism was analyzed using co-immunoprecipitation (co-IP), IP, immunofluorescence staining, bioinformatic analysis and western blot. Results showed that Kae decreased the content of intracellular TG and TC, inhibited cellular lipid accumulation, and reduced the expression of FAS, ACC and SREBP-1c in cell model. Moreover, Kae increased the level of ADMA and PRMT-1, and PRMT-1 knockdown reversed the effect of Kae inhibiting lipid accumulation in cell model. Mechanistically, PRMT-1 overexpression inhibited arginine methylation of SCD1 at arginine (R)175 site. In concluiosn, kae inhibited lipid accumulation in AFLD cell model through PRMT-1-mediated SCD1 arginine methylation. This study may provide a novel therapeutic strategy for AFLD.
Indexed as
Identifiers
40775267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.